ANIP vs EMBC: fair value comparison
ANI Pharmaceuticals, Inc. and Embecta Corp. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EMBC currently sits closer to the top of our discount ranking. ANIP carries the stronger quality grade.
| ANIP | EMBC | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $71.92 | $5.25 |
| 12-month range | $71.92–$94.06 | $3.28–$14.24 |
| Sector rank | #11 of 113 Healthcare | #10 of 113 Healthcare |
| Quality grade | A | B |
| Momentum grade | — | B |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Downtrend |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: ANIP fair value analysis · EMBC fair value analysis